» Articles » PMID: 10594402

Behaviour of Saccharomyces Boulardii in Recurrent Clostridium Difficile Disease Patients

Overview
Date 1999 Dec 14
PMID 10594402
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite recent interest in therapeutic microorganisms taken orally, little is known about the pharmacodynamics of these agents in a target population of patients with disease. The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy.

Methods: Patients with recurrent CDD all received a 10-day standard antibiotic regimen together with 28 days of S. boulardii or placebo. Stool samples were collected from patients at various time points and assayed for S. boulardii.

Results: The mean concentration of S. boulardii of patients who recurred was 2.5 x 104 CFU/g compared to 1 x 106 CFU/g in patients that did not recur (P=0.02). Patients with low yeast concentrations in their stools (<104/g) recurred more often (14/15, 93%) compared with patients with higher levels (19/35, 54%, P=0.007). Clearance of S. boulardii was rapid; only 4% had positive stools 3 days after stopping dosing.

Conclusions: After chronic dosing of S. boulardii, patients with low stool concentrations had a higher likelihood of recurrence of CDD. Stool concentrations were also lower during periods of diarrhoea. These results show the importance of characterizing the dynamics of a therapeutic microorganism in patients with disease, as kinetic studies in healthy volunteers may not give a true reflection of the disturbed microecology in the disease state.

Citing Articles

Yeast oral vaccines against infectious diseases.

Austriaco N Front Microbiol. 2023; 14:1150412.

PMID: 37138614 PMC: 10149678. DOI: 10.3389/fmicb.2023.1150412.


How Gut Bacterial Dysbiosis Can Promote Overgrowth during Colonic Inflammation.

Jawhara S Microorganisms. 2022; 10(5).

PMID: 35630457 PMC: 9147621. DOI: 10.3390/microorganisms10051014.


Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.

Jin Y, Yu S, Liu J, Yun E, Lee J, Jin Y Microb Cell Fact. 2021; 20(1):160.

PMID: 34407819 PMC: 8371797. DOI: 10.1186/s12934-021-01644-w.


A probiotic yeast-based immunotherapy against infection.

Chen K, Zhu Y, Zhang Y, Hamza T, Yu H, Saint Fleur A Sci Transl Med. 2020; 12(567).

PMID: 33115949 PMC: 7692727. DOI: 10.1126/scitranslmed.aax4905.


Recovery of CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration.

Decherf A, Dehay E, Boyer M, Clement-Ziza M, Rodriguez B, Legrain-Raspaud S Nutrients. 2020; 12(8).

PMID: 32722250 PMC: 7468903. DOI: 10.3390/nu12082211.